|
|
Volumn 32, Issue 6, 2009, Pages 347-348
|
|
Safety of spironolactone use in ambulatory heart failure patients
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOTENSIN RECEPTOR ANTAGONIST;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
BETA ADRENERGIC RECEPTOR STIMULATING AGENT;
CALCIUM CHANNEL BLOCKING AGENT;
CREATININE;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
INSULIN;
LOOP DIURETIC AGENT;
NONSTEROID ANTIINFLAMMATORY AGENT;
POTASSIUM;
SPIRONOLACTONE;
THIAZIDE DIURETIC AGENT;
AGED;
AMBULATORY CARE;
CHRONIC KIDNEY DISEASE;
CLINICAL TRIAL;
CONGESTIVE HEART FAILURE;
CONTROLLED CLINICAL TRIAL;
CREATININE BLOOD LEVEL;
DRUG SAFETY;
FEMALE;
GLOMERULUS FILTRATION RATE;
HEART EJECTION FRACTION;
HOSPITAL ADMISSION;
HUMAN;
HYPERKALEMIA;
LETTER;
MAJOR CLINICAL STUDY;
MALE;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIAL;
RETROSPECTIVE STUDY;
RISK;
SYSTOLIC HEART FAILURE;
TERTIARY HEALTH CARE;
AGED;
ALDOSTERONE ANTAGONISTS;
AMBULATORY CARE;
BIOLOGICAL MARKERS;
CHRONIC DISEASE;
CREATININE;
EVIDENCE-BASED MEDICINE;
FEMALE;
HEART FAILURE;
HUMANS;
HYPERKALEMIA;
KIDNEY DISEASES;
MALE;
POTASSIUM;
RETROSPECTIVE STUDIES;
RISK ASSESSMENT;
RISK FACTORS;
SPIRONOLACTONE;
|
|
EID: 67650481229
PISSN: 01609289
EISSN: None
Source Type: Journal
DOI: 10.1002/clc.20597 Document Type: Letter |
|
Times cited : (1)
|
|
References (2)
|
